Wanjia Group Holdings Ltd
Wanjia Group Holdings Ltd has a liquidity position characterized by a current ratio of 1.95, indicating a moderate ability to meet short-term obligations. The company holds HKD 24,083,000 in cash and equivalents, which is a significant portion of its total assets of HKD 106,822,000. However, the company reported negative operating income of HKD -4,089,000 and a net loss of HKD -6,616,000, suggesting operational challenges. The company's profitability metrics are below typical industry benchmarks. The return on equity (ROE) is -9.89%, and the return on assets (ROA) is -6.19%, both indicating poor capital efficiency and asset utilization. These figures are particularly concerning in the healthcare sector, where consistent returns are essential for sustaining operations and reinvestment. Wanjia Group Holdings Ltd operates through two primary segments: pharmaceutical wholesale and distribution, and hemodialysis treatment and consultancy services. The financial data does not provide a breakdown of revenue by segment, but the company's operations are likely concentrated in these two areas. There is no indication of geographic diversification in the provided data, suggesting potential revenue concentration risks. The company's growth trajectory is uncertain. The most recent financial data shows a net loss, and there is no indication of a significant revenue increase in the near term. The capital expenditure of HKD -732,000 suggests minimal investment in new projects or expansion, which could limit future growth opportunities. Risk factors for Wanjia Group Holdings Ltd include its negative net income and operating income, which could affect its ability to service debt and maintain operations. The company's debt-to-equity ratio of 0.32 is relatively low, indicating a conservative capital structure. However, the liquidity risk is classified as low, and there are no immediate filing-based liquidity or dilution flags. Recent events and filings do not indicate any significant changes in the company's operations or financial status. The absence of dilution flags and the low dilution risk suggest that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.
Business. Wanjia Group Holdings Ltd operates in the healthcare sector, primarily through pharmaceutical wholesale and distribution and hemodialysis treatment and consultancy services.
Classification. Wanjia Group Holdings Ltd is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.
- Wanjia Group Holdings Ltd has a current ratio of 1.95, indicating a moderate ability to meet short-term obligations.
- The company reported a net loss of HKD -6,616,000 and negative operating income of HKD -4,089,000, suggesting operational challenges.
- The return on equity (ROE) is -9.89%, and the return on assets (ROA) is -6.19%, both indicating poor capital efficiency and asset utilization.
- The company's operations are concentrated in two segments: pharmaceutical wholesale and distribution, and hemodialysis treatment and consultancy services.
- The company's growth trajectory is uncertain, with minimal capital expenditure and no significant revenue increase in the near term.
- The company has a low liquidity risk and no immediate filing-based liquidity or dilution flags.
- --
- ## RATIONALES
- No immediate filing-based liquidity or dilution flags were detected.